title: Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension.
abstract: Pulmonary arterial hypertension (PAH) is a syndrome in which pulmonary vascular cross sectional area and compliance are reduced by vasoconstriction, vascular remodeling, and inflammation. Vascular remodeling results in part from increased proliferation and impaired apoptosis of vascular cells. The resulting increase in afterload promotes right ventricular hypertrophy (RVH) and RV failure. Recently identified mitochondrial-metabolic abnormalities in PAH, notably pyruvate dehydrogenase kinase-mediated inhibition of pyruvate dehydrogenase (PDH), result in aerobic glycolysis in both the lung vasculature and RV. This glycolytic shift has diagnostic importance since it is detectable early in experimental PAH by increased lung and RV uptake of (18)F-fluorodeoxyglucose on positron emission tomography. The metabolic shift also has pathophysiologic and therapeutic relevance. In RV myocytes, the glycolytic switch reduces contractility while in the vasculature it renders cells hyperproliferative and apoptosis-resistant. Reactivation of PDH can be achieved directly by PDK inhibition (using dichloroacetate), or indirectly via activating the Randle cycle, using inhibitors of fatty acid oxidation (FAO), trimetazidine and ranolazine. In experimental PAH and RVH, PDK inhibition increases glucose oxidation, enhances RV function, regresses pulmonary vascular disease by reducing proliferation and enhancing apoptosis, and restores cardiac repolarization. FAO inhibition increases RV glucose oxidation and RV function in experimental RVH. The trigger for metabolic remodeling in the RV and lung differ. In the RV, metabolic remodeling is likely triggered by ischemia (due to microvascular rarefaction and/or reduced coronary perfusion pressure). In the vasculature, metabolic changes result from redox-mediated activation of transcription factors, including hypoxia-inducible factor 1α, as a consequence of epigenetic silencing of SOD2 and/or changes in mitochondrial fission/fusion. Randomized controlled trials are required to assess whether the benefits of enhancing glucose oxidation are realized in patients with PAH.
authors: Department of Medicine, Queen's University, Kingston, Ontario, Canada.
authors: Stephen L
authors: SL
authors: Archer
authors: Yong-Hu
authors: YH
authors: Fang
authors: John J
authors: JJ
authors: Ryan
authors: Lin
authors: L
authors: Piao
keywords: aerobic glycolysis; fatty acid oxidation; pyruvate dehydrogenase kinase; right ventricular ischemia; the Randle cycle
references: Kardiol Pol. 2008 Oct;66(10):1033-9; discussion 1040-1
references: 19006024
references: Haematologica. 2006 Jun;91(6):722
references: 16769565
references: Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1342-7
references: 17227868
references: Epigenetics. 2006 Oct-Dec;1(4):163-71
references: 17965603
references: Eur Respir J. 2008 Jun;31(6):1160-6
references: 18216049
references: Cardiovasc Drugs Ther. 1990 Aug;4 Suppl 4:814-5
references: 1965528
references: J Cell Biochem. 1994;55 Suppl:1-11
references: 7929613
references: Am J Physiol Lung Cell Mol Physiol. 2001 Jul;281(1):L202-8
references: 11404263
references: J Mol Cell Cardiol. 1996 Feb;28(2):341-50
references: 8729066
references: Circulation. 1981 Jan;63(1):87-95
references: 7438411
references: Biochem J. 2000 Dec 15;352 Pt 3:731-8
references: 11104680
references: Cardiovasc Res. 1997 Feb;33(2):243-57
references: 9074687
references: Science. 1999 Oct 15;286(5439):481-6
references: 10521337
references: Circ Res. 2012 May 25;110(11):1484-97
references: 22511751
references: Chest. 2010 Nov;138(5):1234-9
references: 21051399
references: J Biol Chem. 1996 Dec 13;271(50):32253-9
references: 8943284
references: Cancer Cell. 2007 Jan;11(1):37-51
references: 17222789
references: Biochem Pharmacol. 1988 Dec 15;37(24):4685-8
references: 2849454
references: J Cardiovasc Magn Reson. 2012 Feb 01;14:11
references: 22296860
references: Lancet. 1963 Apr 13;1(7285):785-9
references: 13990765
references: Am J Respir Crit Care Med. 2004 Mar 15;169(6):764-9
references: 14701708
references: J Am Coll Cardiol. 2005 Jun 7;45(11):1849-55
references: 15936618
references: J Mol Med (Berl). 2010 Jan;88(1):47-60
references: 19949938
references: J Mol Med (Berl). 2012 Jan;90(1):31-43
references: 21874543
references: J Pathol. 2001 Oct;195(3):367-74
references: 11673836
references: Blood. 2005 Jan 15;105(2):659-69
references: 15374877
references: Nat Clin Pract Cardiovasc Med. 2006 Sep;3(9):490-8
references: 16932766
references: J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S43-S54
references: 19555858
references: Circulation. 2009 Nov 17;120(20):1951-60
references: 19884466
references: Eur Respir J. 2012 Apr;39(4):939-44
references: 21885398
references: Circulation. 2006 Jun 6;113(22):2630-41
references: 16735674
references: Br J Cancer. 2008 Oct 7;99(7):989-94
references: 18766181
references: Circulation. 2002 Jan 15;105(2):244-50
references: 11790708
references: Free Radic Biol Med. 2008 Dec 1;45(11):1573-80
references: 18845242
references: Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H570-8
references: 18083891
references: Am J Pathol. 2010 Mar;176(3):1130-8
references: 20110409
references: Am J Respir Crit Care Med. 2003 Feb 15;167(4):580-6
references: 12446266
references: Am J Physiol. 1998 Jul;275(1):H169-75
references: 9688910
references: J Clin Invest. 2010 Mar;120(3):827-39
references: 20197624
references: Mol Genet Metab. 2012 Jul;106(3):385-94
references: 22896851
references: Chest. 2003 Feb;123(2):344-50
references: 12576350
references: Circ Res. 2007 Mar 30;100(6):923-9
references: 17332430
references: FASEB J. 2012 May;26(5):2175-86
references: 22321727
references: Eur Respir J. 2010 Jun;35(6):1286-93
references: 19897557
references: Circulation. 2008 Sep 16;118(12):1250-8
references: 18765391
references: Circulation. 2003 Aug 19;108(7):844-8
references: 12900346
references: Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H1185-92
references: 14630626
references: Circ Res. 1982 Sep;51(3):371-84
references: 6126283
references: Circ Res. 2004 Oct 15;95(8):830-40
references: 15375007
references: J Heart Lung Transplant. 1996 Jan;15(1 Pt 1):100-5
references: 8820089
references: J Clin Invest. 1999 Mar;103(5):691-6
references: 10074486
references: Am J Respir Crit Care Med. 2012 Mar 15;185(6):670-9
references: 22246173
references: Circ Res. 2000 Mar 17;86(5):580-8
references: 10720420
references: FASEB J. 2009 Dec;23(12):4135-47
references: 19679640
references: Eur Heart J. 2008 Jan;29(1):120-7
references: 18065750
references: Sci Transl Med. 2010 Aug 11;2(44):44ra58
references: 20702857
references: Sci Transl Med. 2010 May 12;2(31):31ra34
references: 20463368
references: J Am Coll Cardiol. 2009 Apr 28;53(17):1510-6
references: 19389561
references: J Am Coll Cardiol. 1993 Oct;22(4):1170-4
references: 8409056
references: Circulation. 2010 Jun 22;121(24):2661-71
references: 20529999
references: Eur Respir J. 2011 Aug;38(2):359-67
references: 21310884
references: Radiology. 2011 Jan;258(1):119-27
references: 20971775
references: Circulation. 1996 Jan 1;93(1):135-42
references: 8616920
references: J Am Coll Cardiol. 2011 Dec 6;58(24):2511-9
references: 22133851
references: PLoS Med. 2006 Jul;3(7):e290
references: 16768548
references: N Engl J Med. 2005 Nov 10;353(19):2042-55
references: 16282179
references: Proc Natl Acad Sci U S A. 1988 Jan;85(2):339-43
references: 2963328